Crosstalk between cancer and haemostasis: Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor

Hamostaseologie

Volumn 32, Issue 2, 2012, Pages 95-104

  Langer, F ^a   Bokemeyer, C ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cancer; Micro particles; Thrombosis; Tissue factor

Indexed keywords

THROMBOPLASTIN;

ANGIOGENESIS; BLOOD CLOTTING; CANCER ASSOCIATED THROMBOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CIRCULATION; HEMOSTASIS; HUMAN; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; BIOLOGICAL MODEL; CELL TRANSFORMATION; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; VEIN THROMBOSIS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HEMOSTASIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 84863463096     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1160     Document Type: Review

References (100)

1. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32(Suppl 1): 61-68.
2. Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol 2001; 2: 608-613.
3. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3: 425-430
4. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50: 187-196.
5. Franchini M, Montagnana M, Targher G et al. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24: 29-38.
6. Seitz R, Rappe N, Kraus M et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 1993; 4: 249-254
7. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001; 31: 388-394
8. Dirix LY, Salgado R, Weytjens R et al. Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395
9. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97: 3044-3052.
10. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-1059.
11. Hjortoe GM, Petersen LC, Albrektsen T et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103: 3029-3037.
12. Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med 2004; 32: S293-S297
13. Naldini A, Bernini C, Pucci A, Carraro F. Thrombinmediated IL-10 up-regulation involves protease-activated receptor (PAR)-1 expression in human mononuclear leukocytes. J Leukoc Biol 2005; 78: 736-744
14. Esmon CT. Does inflammation contribute to thrombotic events? Haemostasis 2000; 30(Suppl 2): 34-40.
15. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci 2010; 67: 499-511.
16. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-972.
17. Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 2009; 15: 1949-1955.
18. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-2380.
19. Allavena P, Garlanda C, Borrello MG et al. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008; 18: 3-10.
20. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5(Suppl 1): 246-254.
21. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723-1729.
22. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002; 3: 27-34.
23. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009; 27: 4902-4911.
24. Menapace LA, Peterson DR, Berry A et al. Symptomatic and incidental thromboses are both associated with mortality in pancreatic cancer. Blood 2010; 116: 3167.
25. Lee AY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009; 27: 4895-4901.
26. Falanga A. Biological and clinical aspects of anticancer effects of antithrombotics. Pathophysiol Haemost Thromb 2003/2004; 33: 389-392.
27. Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 2008; 34: 154-160
28. Chinen K, Kazumoto T, Ohkura Y et al. Pulmonary tumor thrombotic microangiopathy caused by a gastric carcinoma expressing vascular endothelial growth factor and tissue factor. Pathol Int 2005; 55: 27-31.
29. Chinen K, Tokuda Y, Fujiwara M, Fujioka Y. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature. Pathol Res Pract 2010; 206: 682-689.
30. Okubo Y, Wakayama M, Kitahara K et al. Pulmonary tumor thrombotic microangiopathy induced by gastric carcinoma: morphometric and immunohistochemical analysis of six autopsy cases. Diagn Pathol 2011; 6: 27.
31. Chinen K, Fujino T, Horita A et al. Pulmonary tumor thrombotic microangiopathy caused by an ovarian cancer expressing tissue factor and vascular endothelial growth factor. Pathol Res Pract 2009; 205: 63-68.
32. Garnier D, Milsom C, Magnus N et al. Role of the tissue factor pathway in the biology of tumor initiating cells. Thromb Res 2010; 125(Suppl 2): S44-S50.
33. Kakkar AK, Lemoine NR, Scully MF et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-1104.
34. Shigemori C, Wada H, Matsumoto K et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80: 894-898.
35. Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998; 79: 19-22.
36. Abdulkadir SA, Carvalhal GF, Kaleem Z et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31: 443-447.
37. Ohta S, Wada H, Nakazaki T et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22: 2991-2996.
38. Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66: 10643-10646.
39. Yu JL, May L, Lhotak V et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734-1741.
40. Milsom CC, Yu JL, Mackman N et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 2008; 68: 10068-10076.
41. Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 2010; 116: 815-818.
42. Rong Y, Belozerov VE, Tucker-Burden C et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009; 69: 2540-2549.
43. Rong Y, Post DE, Pieper RO et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65: 1406-1413.
44. Yan J, Wang K, Dong L et al. PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association. Proc Natl Acad Sci USA 2010; 107: 3716-3721.
45. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006; 65: 529-539.
46. Regina S, Valentin JB, Lachot S et al. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem 2009; 55: 1834-1842.
47. Yu J, May L, Milsom C et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 2008; 28: 1975-1981.
48. Hobbs JE, Zakarija A, Cundiff DL et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007; 120(Suppl 2): S13-S21.
49. Signaevsky M, Hobbs J, Doll J et al. Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis. Semin Thromb Hemost 2008; 34: 161-169.
50. Palumbo JS, Kombrinck KW, Drew AF et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-3309.
51. Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008; 34: 147-153.
52. Rydén L, Grabau D, Schaffner F et al. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 2010; 126: 2330-2340.
53. Abe K, Shoji M, Chen J et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96: 8663-8668.
54. Dorfleutner A, Hintermann E, Tarui T et al. Crosstalk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell 2004; 15: 4416-4425.
55. Ott I, Fischer EG, Miyagi Y et al. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140: 1241-1253.
56. van den Berg YW, van den Hengel LG, Myers HR et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA 2009; 106: 19497-19502.
57. Ahamed J, Versteeg HH, Kerver M et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 2006; 103: 13932-13937.
58. Versteeg HH, Schaffner F, Kerver M et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008 111: 190-199.
59. Uno K, Homma S, Satoh T et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007; 96: 290-295.
60. Khorana AA, Ahrendt SA, Ryan CK et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870-2875.
61. de Meis E, Azambuja D, Ayres-Silva JP et al. Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. Braz J Med Biol Res 2010; 43: 403-408.
62. Del Conde I, Bharwani LD, Dietzen DJ et al. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007; 5: 70-74.
63. Tesselaar ME, Romijn FP, Van Der Linden IK et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007; 5: 520-527.
64. Tesselaar ME, Romijn FP, van der Linden IK et al. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost. 2009; 7: 1421-1423.
65. Manly DA, Wang J, Glover SL et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010; 125: 511-512.
66. Campello E, Spiezia L, Radu CM et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011; 127: 473-477.
67. Khorana AA, Francis CW, Menzies KE et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6: 1983-1985.
68. Zwicker JI, Liebman HA, Neuberg D et al. Tumorderived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-6840.
69. Langer F, Spath B, Haubold K et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascularcoagulation. Ann Hematol 2008; 87: 451-457.
70. Østerud B. Tissue factor expression in blood cells. Thromb Res 2010; 125(Suppl 1): S31-S34.
71. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284-1297.
72. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004; 2: 2065-2067.
73. Hron G, Kollars M, Weber H et al. Tissue factorpositive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
74. Haubold K, Rink M, Spath B et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009; 101: 1147-1155.
75. Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost 2010; 36: 865-875.
76. Davila M, Amirkhosravi A, Coll E et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 6: 1517-1524.
77. Thomas GM, Panicot-Dubois L, Lacroix R et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206: 1913-1927.
78. Nieuwland R. Cellular origin of microparticles exposing tissue factor in cancer: a mixed double? J Thromb Haemost 2008; 6: 1514-1516.
79. Ueno T, Toi M, Koike M et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164-70
80. Han LY, Landen CN Jr, Kamat AA et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006; 24: 755-761.
81. Langer F, Chun FK, Amirkhosravi A et al. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost 2007; 97: 464-470.
82. Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36: 888-906.
83. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-11836.
84. Im JH, Fu W, Wang H et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004; 64: 8613-8619.
85. Palumbo JS, Talmage KE, Massari JV et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-185.
86. Amirkhosravi A, Mousa SA, Amaya M et al. Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Methods Mol Biol 2010; 663: 241-259.
87. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant lowmolecular-weight heparin versus the standard lowmolecular-weight heparin, enoxaparin. Thromb Haemost 2006; 96: 816-821.
88. Ludwig RJ, Alban S, Bistrian R et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006; 95: 535-540.
89. Langer F, Amirkhosravi A, Ingersoll SB et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost. 2006; 4: 1056-1062.
90. Falati S, Liu Q, Gross P et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-1598.
91. Brüggemann LW, Versteeg HH, Niers TM et al. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med 2008; 12: 2622-2627.
92. Amirkhosravi A, Meyer T, Chang JY et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002; 87: 930-936.
93. Zhao J, Aguilar G, Palencia S et al. rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res 2009; 15: 208-216.
94. Carneiro-Lobo TC, Konig S, Machado DE et al. Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J Thromb Haemost. 2009; 7: 1855-1864.
95. Amarzguioui M, Peng Q, Wiiger MT et al. Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 2006; 12: 4055-4061.
96. Ndungu JM, Lu YJ, Zhu S et al. Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation. J Med Chem 2010; 53: 3127-3132.
97. Duanmu J, Cheng J, Xu J, Booth CJ, Hu Z. Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. Br J Cancer. 2011; 104: 1401-1409.
98. Cocco E, Hu Z, Richter CE et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer 2010; 103: 812-819.
99. Schwöppe C, Kessler T, Persigehl T et al. Tissue-factor fusion proteins induce occlusion of tumor vessels. Thromb Res 2010; 125(Suppl 2): S143-S150.
100. Morrow DA, Murphy SA, McCabe CH et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 2005; 26: 682-688.